WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) announced the
FDA has extended the approval of Praluent as an adjunct to diet and other
low-density lipoprotein cholesterol lowering therapies to include pediatric
patients aged 8 and older with heterozygous familial hypercholesterolemia. The
approval was based on a phase 3, randomized multicenter trial.

'The approval of Praluent for the treatment of high cholesterol was a historic
landmark achievement, as it was the first approved therapy targeting the
genetically-validated PCSK9 target for heart disease,' said George Yancopoulos,
President and Chief Scientific Officer at Regeneron, and a principal inventor of
Praluent.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX